Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy L Rose

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Cancer|January 5, 2024
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockadeEric J Miller, Tracy L Rose, Benjamin L Maughan, et al.
Plos One|December 31, 2021
Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancerStephanie I Kim, Andy H Szeto, Katherine P Morgan, et al.
Plos One|June 21, 2021
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancerStephanie I Kim, Andy H Szeto, Katherine P Morgan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2020
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)Rana R McKay, Bradley A McGregor, Wanling Xie, et al.
British Journal of Cancer|October 9, 2018
Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapyTracy L Rose, David D Chism, Ajjai S Alva, et al.
Clinical Genitourinary Cancer|May 16, 2023
Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional StudyCorbin J Eule, Junxiao Hu, Sulaiman Al-Saad, et al.
European Urology|December 13, 2023
Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder CancerWolfgang Beckabir, Sara E Wobker, Jeffrey S Damrauer, et al.
The Journal of Clinical Investigation|August 16, 2021
Entinostat induces antitumor immune responses through immune editing of tumor neoantigensAndrew S Truong, Mi Zhou, Bhavani Krishnan, et al.
Urologic Oncology|July 1, 2015
Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settingsTracy L Rose, Allison M Deal, Ethan Basch, et al.
Cancer Research Communications|August 8, 2024
Poor Prognosis among Radiation-Associated Bladder Cancer Is Defined by Clinicogenomic FeaturesN Ari Wijetunga, Kathryn H Gessner, Krishna Kanchi, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Cancer|January 5, 2024
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockadeEric J Miller, Tracy L Rose, Benjamin L Maughan, et al.
Plos One|December 31, 2021
Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancerStephanie I Kim, Andy H Szeto, Katherine P Morgan, et al.
Plos One|June 21, 2021
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancerStephanie I Kim, Andy H Szeto, Katherine P Morgan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2020
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)Rana R McKay, Bradley A McGregor, Wanling Xie, et al.
British Journal of Cancer|October 9, 2018
Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapyTracy L Rose, David D Chism, Ajjai S Alva, et al.
Clinical Genitourinary Cancer|May 16, 2023
Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional StudyCorbin J Eule, Junxiao Hu, Sulaiman Al-Saad, et al.
European Urology|December 13, 2023
Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder CancerWolfgang Beckabir, Sara E Wobker, Jeffrey S Damrauer, et al.
The Journal of Clinical Investigation|August 16, 2021
Entinostat induces antitumor immune responses through immune editing of tumor neoantigensAndrew S Truong, Mi Zhou, Bhavani Krishnan, et al.
Urologic Oncology|July 1, 2015
Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settingsTracy L Rose, Allison M Deal, Ethan Basch, et al.
Cancer Research Communications|August 8, 2024
Poor Prognosis among Radiation-Associated Bladder Cancer Is Defined by Clinicogenomic FeaturesN Ari Wijetunga, Kathryn H Gessner, Krishna Kanchi, et al.
Pageof 7